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The involvement of Gi proteins in the modulation of pain perception has been widely
established, and mutations in G-proteins have already been identified as the aetio-
pathological cause of human diseases. The aim of the present study was to determine
whether a deficiency or a hypofunctionality of the Gi proteins occurred in primary
headache. The functionality and the level of expression of Gi proteins were investigated
in lymphocytes from migraine without aura, migraine with aura and cluster headache
sufferers. A reduced capability to inhibit forskolin-stimulated adenylyl cyclase activity
in headache patients was observed. Migraine patients also showed basal adenosine
cAMP levels about four times higher than controls. The reduced activity of Gi proteins
seems not to be related to a reduction of protein levels since no significant reduction of
the Gia subunits was observed. These results indicate Gi protein hypofunctionality as
an aetiopathogenic mechanism in migraine and cluster headache. u Migraine, cluster
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Introduction
Headache is the most common pain syndrome. It is
also the most frequent symptom in neurology, where it
may be a disease in itself (primary headache) or indicate
an underlying local or systemic disease (secondary
headache). In the complete absence of physical and
laboratory alterations, diagnosis of primary headache
remains purely clinical, based on the detailed descrip-
tion of symptoms by the patients. The criteria for
classification of headache disorders was proposed in
1988 by the International Headache Society (IHS) (1)
that classified primary headache into three major clinical
subtypes: migraine, cluster headache and tension-type
headache. Migraine is a multifaceted disorder of which
the head pain is only one component. It is an extremely
frequent and sometimes incapacitating condition and
female preponderance is a characteristic feature (2).
The two most frequent varieties of migraine are
migraine without aura and migraine with aura in
which neurological symptoms precede or accompany
the headache (2).
Numerous factors can trigger or predispose to
migraine attack. Some are identifiable, such as stress,
hormonal and dietary factors, while the majority remain
unknown. The exact pathogenesis of primary headache
is, indeed, still unknown. Many theories have been
elaborated, but none can account for all the clinical
features and pathophysiological aspects of this syn-
drome. The ‘vascular’ hypothesis, which states that
the headache phase of migrainous attacks is caused
by vasodilatation and that the neurologic symptoms,
occurring during the migraine prodrome, are produced
by intracranial vasoconstriction (3), was widely accepted
for many years. The ‘serotoninergic’ hypothesis impli-
cated a primary neuronal origin in migraine which may
represent a hereditary perturbation of serotoninergic
neurotransmission. It was found that platelet levels of
serotonin fall consistently at the onset of headache and
migrainous episodes may be triggered by drugs that
release this biogenic amine from tissue store (4). The
‘trigeminovascular’ hypothesis is one of the most accep-
ted theories of migraine origin. A depolarization of the
trigeminal ganglions or its perivascular nerve terminals
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activates the trigeminovascular system, giving rise to
central transmission of nociceptive information and
retrograde perivascular release of powerful vasoactive
neuropeptides, such as CGRP, substance P, neurokinin
A (5, 6). In more recent years, however, it was supposed
that in migraine both vascular and neural components
are relevant and most probably interrelated (7). Recently,
‘neuronal hyperexcitability’ has been proposed as the
biological basis for susceptibility to migraine. Enhanced
excitability of cell membrane, perhaps in part genetically
determined, renders the brain susceptible to attacks.
Factors that increase or decrease neuronal excitability
determine the threshold for triggering attacks (8). How-
ever, from the numerous studies conducted so far,
no single receptor abnormality has emerged that can
completely explain why some people are more prone
to suffer from migraine than others. These considera-
tions led us to look beyond the receptor at the more
universally distributed components of cell signalling
that are G-proteins.
Nearly all inhibitory neurotransmitters able to enhance
the pain threshold utilize Gi proteins as signal transduc-
tion system. G-proteins are heterotrimeric molecules
with a, b and c subunits. The a subunits can be classified
into families, depending on whether they are targets for
cholera toxin (Gs), pertussis toxin (Gi and Go) or neither
(Gq and G12) (9). Gi proteins represent the most wide-
spread modulatory signalling pathway in neurones
(10) and are responsible for inhibition of adenylate
cyclase activity and modulation of several K+ and Ca2+
channels in order to reduce cell excitability (11, 12).
Involvement of Gi proteins in the modulation of pain
perception has been well established. The administra-
tion of pertussis toxin, which selectively inactivates
Gi proteins (13), produced hyperalgesia and allodynia
in laboratory animals (14, 15), clearly indicating that
a lack of functionality of Gi proteins enhances the
sensitivity to pain. Hypofunctionality of Gi proteins
also produced insensitivity to analgesic treatments. It
has been observed that pertussis toxin prevents the
enhancement of the pain threshold induced by widely
used analgesic drugs such as opioids, antihistamines,
and tricyclic antidepressants (14, 16, 17).
Mutations in G-proteins have already been identified
as the aetiopathological cause of human diseases. Alter-
ations at Gsa subunit level have been observed in the
Albright hereditary osteodystrophy, an autosomic domi-
nant genetic pathology, as well as in the acromegaly,
hyperfunctional tyroid nodules and McCune–Albright
syndrome (18).
The aim of the present study was to determine
whether a deficiency or a hypofunctionality of the
Gi proteins occurs in headache. The functionality
and expression levels of Gi proteins were therefore
investigated in lymphocytes from patients with clinically
well-defined primary headache.
Patients and methods
Participants
Eighteen healthy volunteers, 21 primary-headache and
12 painful-disease (neuropathic pain, arthrosis, rheuma-
toid arthritis) sufferers participated in the study after
informed consent was obtained from all. Patients were
drug-free for a period of at least 1 week and had
undergone laboratory and physical examination to
exclude the presence of other concomitant infections.
Furthermore, healthy subjects had no headache familial
history. Patients suffering from primary headache were
clinically classified following the criteria established by
the IHS (1) and divided into three subgroups: migraine
without aura, migraine with aura and cluster headache.
Patients belonging to the painful diseases group were
classified as suffering from arthrosis, rheumatoid
arthritis and neuropathic pain mainly deriving from
entrapment syndromes. For all patients the visual
analogue scale (VAS) value, which represents an
arbitrary indication of the pain experienced during the
attack, was evaluated. Blood samples were collected
during the quiescent state (period between migraine
attacks or cluster periods) and experiments were
performed in blind.
Adenylyl cyclase activity assay
Lymphocytes were isolated as described by Bo¨yum (19).
Mononuclear cell counts were made. After permeabili-
zation with the detergent digitonin (10 mg/ml) (20),
lymphocytes from healthy subjects were preincubated
with or without pertussis toxin (PTX) at the concentra-
tion of 100 ng/ml at 37uC for 90 min, whereas lympho-
cytes from headache and painful disease sufferers
were all preincubated without PTX. After preincuba-
tion, lymphocytes (1–2 3 106 intact cells/assay) were
incubated either with the vehicle dimethyl sulph-
oxide (DMSO) or forskolin 10x4 M which started
the 3k,5k-cyclic monophosphate (cAMP) formation (21).
To obtain the inhibition curve of cAMP production,
the non-hydrolysable analogue of GTP Gpp(NH)p(5k-
guanylylimidodiphosphate) was added to the forskolin-
containing samples in the range of concentrations
from 10 nM to 100 mM in a final volume of 300 ml. After
a 15-min incubation at 37uC, the cells were lysed and
the sample centrifuged according to Brodde et al. (22).
The cAMP content was determined in a 100-ml aliquot
of the supernatant using an enzyme immunoassay kit.
Protein was determined by bicinchoninic acid protein
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assay kit with bovine serum albumin (BSA) as standard.
All assays were performed in duplicate.
Western blot analysis
Aliquot of lymphocyte lysates (100 ml), or recombinant
Gi2a and Gi3a, used as reference proteins, were boiled
for 5 min with 30 ml of sample buffer (4% SDS, 20%
glycerol, 10% 2-mercaptoethanol, 125 mM Tris–HCl,
0.002% bromophenol blue at pH 8). The mixture
(10 mg of proteins for each sample) was separated by
electrophoresis on polyacrylamide/SDS gel according to
Laemli (23) using 10% acrylamide in the running gel.
Following electroblotting to nitrocellulose membranes
(Hybond-ECL 0.45 mm; Amersham, Milan, Italy) (24),
blots were preblocked for 90 min at room temperature
with TBS supplemented with 3% BSA. Following two
washes (10 min each) with T–TBS (TBS containing 0.5%
Tween 20) at room temperature, blots were incubated
overnight at 4uC in TBS supplemented with antisera
suspension (a 1 : 2000 for anti-Gi2a and 1 : 10 000 working
dilutions for Gi3a). Following removal of antisera, blots
were washed twice for 10 min with T–TBS at room
temperature. Thereafter each blot was incubated with
T–TBS supplemented with a second monoclonal goat
anti-rabbit peroxide conjugate antibody (1 : 5000 work-
ing dilution) for 1 h at room temperature. Blots were
then extensively washed (1 h) with several changes of
T–TBS.
Specific bands were detected using the ECL system
(Amersham) according to the manufacturer’s instruc-
tions. (Densitometric analysis of the bands obtained
was carried out using the Scion image program.)
Statistical analysis
Results are given as the means¡SEM. An analysis of
variance (ANOVA), followed by Fisher’s Protected Least
Significant Difference (PLSD) procedure for post hoc
comparison, was used to verify the significance of
differences between two means. Data were analysed
with the StatView software for the Macintosh (1992).
Results
Clinical characteristics of patients
As reported in Table 1, all patient groups showed a com-
parable VAS value indicating homogeneity of intensity
of pain experienced. Laboratory values in patients
affected by headache were similar to healthy controls
(data not shown).
Evaluation of Gi protein functionality
The functionality of Gi proteins was assessed in peri-
pheral blood intact lymphocytes by investigating their
ability to inhibit adenylyl cyclase activity. We first
stimulated adenylyl cyclase by using forskolin 10x4 M.
The inhibition of cAMP production by Gi proteins was
started by administration of Gpp(NH)p in the concen-
tration range of 10x8–10x4 M. In lymphocytes from
healthy subjects Gpp(NH)p produced a dose-dependent
inhibition of forskolin-stimulated adenylyl cyclase
activity detectable by a reduction of cAMP levels of
about 40%. By contrast, no modification of cAMP levels
was observed after preincubation of lymphocytes with
PTX. However, when lymphocytes from headache
patients were used, Gpp(NH)p failed to inhibit adenylyl
cyclase activity, giving an effect similar to that produced
by PTX (Fig. 1a). Investigating the subtypes of primary
headache, we observed an impaired inhibition of
adenylyl cyclase activity in lymphocytes from migraine
without aura, migraine with aura and cluster headache
sufferers (Fig. 1b).
Increasing concentrations of Gpp(NH)p produced
a dose-dependent reduction of cAMP levels in lympho-
cytes from neuropathic pain sufferers, patients affected
by rheumatoid arthritis or arthrosis similar to that
observed in healthy subjects. The values indicating the
adenylyl cyclase activity were reported as difference
(D) between forskolin and forskolin+Gpp(NH)p 10x5 M
cAMP values in order to obtain more detailed informa-
tion about the Gi protein functionality of each patient.
The D values of all groups of headache sufferers were
significantly different from both healthy subjects and
patients affected by painful diseases (Fig. 2).
Determination of cAMP basal levels
Under standard conditions of assay, in healthy sub-
jects basal levels of cAMP were 21.2¡2.6 pmol/mg
protein. Even if there was no statistically significant
correlation of cAMP levels with age or sex, older subjects
showed tendentially slightly higher levels of cAMP (data
not shown). Primary headache patients showed a highly
significant enhancement of basal cAMP levels when
compared with healthy subjects. This effect was parti-
cularly evident in patients suffering from migraine
with or without aura rather than in cluster headache
sufferers, since the cAMP basal levels where, respect-
ively, about four times and twice higher than controls.
By contrast, the basal cAMP levels of patients suffer-
ing from neuropathic pain, arthrosis and rheumatoid
arthritis were not statistically different from healthy
subjects. Patients with arthrosis differed from other
groups because, even if they maintain Gi protein
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functionality, they showed higher levels of cAMP
(Fig. 3).
By comparing forskolin-stimulated levels of cAMP,
no statistically significant difference was seen among
values observed in healthy subjects and in all the
investigated groups of patients (Fig. 3).
Quantitative determination of Gia levels
The expression of Gia and of the subtypes Gi2a and
Gi3a proteins were investigated. As illustrated in Fig. 4,
levels of Gia, Gi2a and Gi3a, quantified by optical densito-
metry, were similar in lymphocytes from both healthy
subjects and headache sufferers. Some representative
examples of Western blot analysis bands are reported
as inset.
Discussion
Present results showed that lymphocytes from head-
ache patients showed a reduced capability to inhibit
forskolin-stimulated adenylyl cyclase activity, clearly
showing a hypofunctionality of Gi proteins. The
observed impaired capability to reduce cAMP levels in
headache sufferers was similar to that produced by
preincubation of lymphocytes from healthy subjects
with pertussis toxin at a concentration consistent with
a complete ADP-ribosylation of Gi proteins (25),
Table 1 Clinical parameters of patients suffering from
headache and painful diseases
Healthy
Sex Age VAS
M 29 0
M 32 0
M 43 0
F 58 0
F 49 0
F 36 0
F 25 0
M 27 0
M 41 0
F 43 0
F 25 0
M 50 0
F 25 0
M 48 0
M 44 0
M 62 0
F 25 0
F 31 0
9 M/9 F 38.5¡2.7
Headache
Sex Age VAS
Migraine without aura
F 53 8.7
F 31 5.7
F 52 8.9
F 49 9.9
F 34 9.9
M 60 7.9
F 57 8.2
F 40 9.1
F 28 7.6
F 31 8.5
1 M/9 F 43.5¡3.8 8.4¡0.4
Migraine with aura
F 30 8.8
F 73 7.5
F 23 7.7
M 38 8.5
M 23 8.3
2 M/3 F 37.4¡8.3 8.2¡0.2
Cluster headache
M 28 9.8
M 51 9.9
M 37 9.9
F 39 9.9
M 36 9.0
M 27 8.3
5 M/1 F 36.3¡3.2 9.4¡0.2
Table 1
(contd.)
Painful diseases
Sex Age VAS
Neuropathic pain
F 60 8.0
M 75 9.3
F 61 5.4
F 72 9.3
F 55 7.3
1 M/4 F 64.6¡3.4 7.9¡0.6
Arthrosis
M 82 9.2
F 60 7.1
F 77 9.6
F 77 3.7
1 M/3 F 74.0¡4.2 7.4¡1.2
Rheumatoid arthritis
F 73 4.6
M 61 2.6
F 75 9.2
1 M/2 F 69.7¡3.6 5.5¡1.6
VAS, Visual analogue scale.
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further indicating a selective hypofunctionality of Gi
proteins. All headache subtypes investigated, even if
they had different clinical characteristics, showed a
similar reduction of inhibitory functionality, suggesting
a fundamental role of Gi proteins in the aetiopatho-
genesis of both migraine and cluster headache.
Lymphocytes from headache suffering subjects
showed higher basal levels of cAMP. These results
indicate that, at resting conditions, there is a disequili-
brium between the inhibitory and stimulatory system
of this enzyme, mediated, respectively, by Gi and Gs
proteins, confirming the hypothesis of a hypofunction-
ality of Gi proteins. An alteration at the level of the
adenylyl cyclase can also be excluded, since the direct
stimulation of the enzyme by forskolin did not reveal
any difference in cAMP levels produced between
patients and healthy subjects.
Among the several classes of compounds that have
been investigated as antimigraine agents, dihydroergot-
amine or triptans represent the reference drugs for acute
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Figure 1 Evaluation of adenylyl cyclase activity in lymphocytes
from healthy and migraine subjects. (A) Lymphocytes from
healthy subjects were preincubated with or without pertussis
toxin (PTX). *P<0.05; **P<0.01 vs. forskolin-stimulated
lymphocytes. s, Healthy; $, headache; u, PTX. (b) Lack of
reduction of cAMP levels in patients suffering from migraine
without aura (MO; &), migraine with aura (MA; u) and
cluster headache (CH; $). *P<0.05 vs. corresponding value
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Figure 2 Evaluation of adenylyl cyclase activity in lymphocytes
from headache patients in comparison with patients suffering
from neuropathic pain, rheumatoid arthritis and arthrosis.
*P<0.05; **P<0.01 vs. healthy group. MO, Migraine without
aura; MA, migraine with aura; CH, cluster headache.
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Figure 3 Evaluation of basal (&) and forskolin-stimulated (u)
cAMP levels in patients suffering from migraine without aura
(MO), migraine with aura (MA), cluster headache (CH),
rheumatoid arthritis, neuropathic pain, and arthrosis. *P<0.05
vs. healthy subjects.
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migraine treatment (26). These compounds exert their
activity by inducing vasoconstriction of cranial vessels,
even if it is not completely elucidated whether these
drugs exert their therapeutic action through an effect on
5-HT1B/D receptors or via a direct effect on vessels (27). It
has long been known that cAMP is a potent vasodilator
of cerebral vessels. The relaxation of vascular smooth
muscle produced by compounds that activate adenylate
cyclase, such as b-adrenergic agents and forskolin, is
thought to depend on their capability to increase the
concentration of cAMP (28). Rosenblum (29) demon-
strated the existence in mice of an adenylyl cyclase–
cAMP system for dilating cerebral arterioles.
Furthermore, it has been reported that a suffusion
with cAMP produced a concentration-dependent sus-
tained vasodilatation of the resting pial arteries in rats
(30). The clinical efficacy of vasoconstrictor agents is
in agreement with our experimental findings. We
observed higher basal levels of cAMP specifically in
migraine patients, and this biochemical alteration could
represent the origin of the vasodilatation which, in turn,
represents the cause triggering the migraine attack.
Further confirmation of this hypothesis is provided by
the observation that among the drugs employed to
prevent effectively migraine attacks are the b-blockers
(3) which are responsible for lowering the intracellular
levels of cAMP.
The most recent theory of headache pathogenesis
considers brain hyperexcitability as the biological basis
for susceptibility to migraine (8). This theory is based
on some studies which showed that occipital cortex
neurones may be hyperexcitable in some 90% of patients
suffering from migraine with aura who experience
visual disturbances as part of their aura (31). Further-
more, psychological studies of visual discrimination
showed that migraine sufferers had a greater sensitivity
for low-level visual processing between attacks, showing
functional impairment of inhibitory interneurones (32).
It has also been reported that cortical and precortical
visual and auditory processing in migraine patients,
investigated by means of pattern-reversal visual evoked
potentials (VEP) and auditory cortical evoked poten-
tials (IDAP), is impaired between attacks (33, 34). Our
results obtained with migraine sufferers are not only
in agreement with the above-mentioned hypothesis,
but the observed hypofunctionality of Gi proteins can
represent the biological mechanism responsible for
the cell hyperexcitability. It is well known, indeed, that
Gi protein activation reduces cell excitability (12). A
deficiency of the Gi protein-mediated inhibitory system
increases cell excitability, leading to a hypersensitivity
to stimuli that can also represent the main cause of the
symptoms experienced by headache sufferers, such as
hypersensitivity to pain, photophobia, phonophobia, etc.
Gi proteins are coupled to many receptor types and
subtypes. It is also well known that Gi protein levels can
be down-regulated at several levels, such as turnover,
transcription, etc., by hormones and neurotransmitters.
Considering that all subjects included in this study
were drug-free for at least 1 week, we can assume that
the observed Gi protein hypofunctionality represents
an individual’s predisposition to headache rather than
a down-regulation produced by the pharmacological
treatment.
It can also be excluded that the observed hypofunc-
tionality of Gi proteins could be an adaptive response
to a condition of chronic pain. Patients suffering from
painful diseases such as neuropathic pain, arthrosis
or rheumatoid arthritis, who experienced pain sensa-
tions comparable to headache sufferers, as indicated
by the VAS values, showed an unaltered Gi protein
functionality.
As the observed hypofunctionality of Gi proteins
could imply a reduction of protein expression, levels of
Gi proteins were determined in cell membrane prepa-
rations from headache sufferers using Western blot
analysis. To this purpose, antibodies against Gia
subunits, which represent the functional subunit of
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Figure 4 Evaluation of Gia protein levels in lymphocytes of
patients suffering from primary headache (M; &) in compari-
son with healthy (H; u) subjects. Data are reported as percen-
tage of corresponding Gia subtype standard. Inset: bands
obtained by Western blot analysis.
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Gi proteins (9), were employed. Furthermore, specific
antibodies against Gi2a and Gi3a subtypes were used,
since Gi2 represents the Gi protein subtype mainly
involved in the inhibitory regulation of adenylyl cyclase
activity in vivo (35) and it plays an important role in the
modulation of pain perception. The administration of
selective antibodies against Gi2a as well as the inhibition
of its expression by the use of specific antisense
oligonucleotides prevented the analgesia induced by
agonists of m-opioid receptors (36, 37). Similarly to Gi2,
Gi3 has also been reported to be involved in pain pro-
cessing, since antibodies against Gi3a prevented d-opioid
analgesia (38). No statistically significant reduction of
Gi protein levels was observed in headache patients,
leading us unable to establish from these data that Gi
protein hypofunctionality is subsequent to a reduction
of protein levels.
The lack of Gi protein reduction seems to be in
contrast to recent data in which a reduction of about
50% of Gi2a mRNA was observed in lymphocytes from
migraine patients (39). These results were obtained using
Northern blot analysis and it is therefore plausible that
this discrepancy could be attributed to the different
recognition sites of the probes used for the determination
of mRNA levels in comparison with those of the anti-
bodies employed for Western blot analysis. The hypo-
functionality of Gi proteins could be, in fact, due to the
presence of a mutation in the protein sequence. In this
condition, the use of a cDNA probe to quantify mRNA
contents, wherever the mutation is located, may show
a level reduction. Conversely, using Western blot
analysis a reduction of Gia protein levels might not
be shown, since the short segment of the protein with
which the employed antibodies interact might not
contain the mutation.
A structural alteration of the Gi proteins in headache
sufferers can be excluded since there was no difference
in the molecular weight of the a subunits of any Gi
protein subtype investigated in comparison with healthy
subjects.
The investigation into Gi protein functionality was
conducted in lymphocytes from peripheral blood taking
into account that Gi proteins have an ubiquitous dis-
tribution (40) and that blood samples can easily be
obtained from patients in a painless manner. Lympho-
cytes represent an appropriate tool to detect Gi protein
functionality since they have cell surface recognition
sites for pertussis toxin, the selective inactivator of Gi,
which are lacking in other blood cell types such as
erythrocytes (41). Lymphocytes have also been widely
used to investigate the aetiopathogenesis of human
diseases at a biochemical and molecular level (42–46).
In conclusion, our results indicate that lympho-
cytes from migraine and cluster headache patients are
distinguishable from lymphocytes not only from healthy
subjects but also from patients suffering from other
painful diseases.
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